These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hirudin as alternative anticoagulant--a historical review. Markwardt F Semin Thromb Hemost; 2002 Oct; 28(5):405-14. PubMed ID: 12420235 [TBL] [Abstract][Full Text] [Related]
3. Hirudin: the famous anticoagulant agent. Markwardt F Adv Exp Med Biol; 1993; 340():191-211. PubMed ID: 8154337 [No Abstract] [Full Text] [Related]
4. The anticoagulant and antithrombotic properties of hirudins. Märki WE; Wallis RB Thromb Haemost; 1990 Nov; 64(3):344-8. PubMed ID: 2096484 [No Abstract] [Full Text] [Related]
5. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban. Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001 [TBL] [Abstract][Full Text] [Related]
6. Lepirudin for heparin-induced thrombocytopenia. Med Lett Drugs Ther; 1998 Sep; 40(1036):94-5. PubMed ID: 9774965 [No Abstract] [Full Text] [Related]
7. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene. Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425 [TBL] [Abstract][Full Text] [Related]
8. Pharmacology and clinical use of bivalirudin. Sciulli TM; Mauro VF Ann Pharmacother; 2002 Jun; 36(6):1028-41. PubMed ID: 12022907 [TBL] [Abstract][Full Text] [Related]
9. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies. Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244 [TBL] [Abstract][Full Text] [Related]
10. Molecular dynamic and pharmacological studies on protein-engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis. Sun Y; Wang B; Pei J; Luo Y; Yuan N; Xiao Z; Wu H; Luo C; Wang J; Wei S; Pei Y; Fu S; Wang D Br J Pharmacol; 2022 Jul; 179(14):3740-3753. PubMed ID: 35135035 [TBL] [Abstract][Full Text] [Related]
12. The development of hirudin as an antithrombotic drug. Markwardt F Thromb Res; 1994 Apr; 74(1):1-23. PubMed ID: 8029805 [No Abstract] [Full Text] [Related]
13. Hirudin in renal insufficiency. Fischer KG Semin Thromb Hemost; 2002 Oct; 28(5):467-82. PubMed ID: 12420243 [TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Callas D; Fareed J Thromb Haemost; 1995 Jul; 74(1):473-81. PubMed ID: 8578509 [TBL] [Abstract][Full Text] [Related]
15. [Anticoagulant therapy with recombinant hirudin in patients with thrombopenia induced by heparin]. Schiele F; Vuillemenot A; Mouhat T; Kieffer Y; Anguenot T; Bernard Y; Bassand JP Presse Med; 1996 May 4-11; 25(16):757-60. PubMed ID: 8692751 [TBL] [Abstract][Full Text] [Related]
16. Future alternatives to heparin: low-molecular-weight heparin and hirudin. Donayre CE; Ouriel K; Rhee RY; Shortell CK J Vasc Surg; 1992 Apr; 15(4):675-82. PubMed ID: 1313932 [TBL] [Abstract][Full Text] [Related]
17. The comeback of hirudin--an old-established anticoagulant agent. Markwardt F Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):10-23. PubMed ID: 2459000 [TBL] [Abstract][Full Text] [Related]
18. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840 [TBL] [Abstract][Full Text] [Related]